38
Participants
Start Date
August 22, 2016
Primary Completion Date
November 27, 2019
Study Completion Date
June 20, 2024
pembrolizumab,
Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
Johns Hopkins School of Medicine The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Merck Sharp & Dohme LLC
INDUSTRY
UNC Lineberger Comprehensive Cancer Center
OTHER